Bioscrip Inc. (NASDAQ:BIOS): Christopher Shackelton And Adam Gray’s Coliseum Capital filed an amended 13D.
You can check out Coliseum Capital’s latest holdings and filings here.
Please follow Coliseum Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Coliseum Capital or update its stock holdings.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Coliseum Capital Management||0||21,514,620||0||21,514,620||21,514,620||14.6%|
|Coliseum Capital Partners||0||13,522,621||0||13,522,621||13,522,621||9.7%|
|Coliseum Capital Partners II||0||3,025,643||0||3,025,643||3,025,643||2.3%|
Page 1 of 10 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Under the Securities Exchange Act of 1934*
(Amendment No. 5)
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
Christopher Shackelton/Adam Gray
105 Rowayton Ave.
Rowayton, CT 06853
Address and Telephone Number of Person Authorized to Receive Notices and Communications)
September 7, 2017
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of sections 240.13d-1(e), 240.13d-1(f) or 140.13d-1(g), check the following box. ☐
The information required on the remainder of
this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
Page 1 of 10